Clinical Trial

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

Name: CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment — clinical trial record (NCT07366112)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DNACDKHR

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Exploring the dynamics of ctDNA following neoadjuvant therapy with CDK4/6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-14

Trial Details

NCT Number	NCT07366112
Lead Sponsor	Peking University People's Hospital
Conditions	Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer, ctDNA Monitoring
Enrollment	158 participants
Start Date	2026-04-20
Primary Completion	2028-01-01 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-13